Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 9:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Scleroderma, Diffuse Clear all
Completed Not applicable Interventional

Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea

NCT01799174
View directory record Official record
Conditions
Scleroderma, Localized, Morphea, Scleroderma, Circumscribed
Interventions
UVA-1 Phototherapy, Placebo
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
6 Years to 95 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Jun 10, 2026, 9:58 AM EDT
Completed Phase 1 Interventional

Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders

NCT00010335
View directory record Official record
Conditions
Systemic Sclerosis, Systemic Lupus Erythematosus, Dermatomyositis, Juvenile Rheumatoid Arthritis, Autoimmune Diseases
Interventions
Stem Cell Transplantation, CD34 selection
Procedure · Device
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
2 Years to 18 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Jun 10, 2026, 9:58 AM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

NCT06308978
View directory record Official record
Conditions
Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Lupus Nephritis
Interventions
FT819, Fludarabine, Cyclophosphamide, Bendamustine
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
12 Years to 70 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2042
U.S. locations
16
States / cities
Beverly Hills, California • Fullerton, California • Irvine, California + 13 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 10, 2026, 9:58 AM EDT
Recruiting Phase 2 Interventional

Sildenafil for Early Pulmonary Vascular Disease in Scleroderma

NCT04797286
View directory record Official record
Conditions
Scleroderma, Mildly Elevated Pulmonary Pressures
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
New Orleans, Louisiana • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jun 10, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis

NCT03041025
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
GSK2330811, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Los Angeles, California • Stanford, California • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Jun 10, 2026, 9:58 AM EDT
Recruiting Not applicable Interventional

Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis

NCT05989763
View directory record Official record
Conditions
Systemic Sclerosis, Constipation, Gastrointestinal Motility Disorder, Autonomic Dysfunction
Interventions
Transcutaneous Electrical Acustimulation (TEA), Sham-TEA
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Jun 10, 2026, 9:58 AM EDT
Terminated Phase 2 Interventional Results available

KD025 in Subjects With Diffuse Cutaneous Systemic Sclerosis

NCT03919799
View directory record Official record
Conditions
System; Sclerosis, Diffuse Cutaneous Systemic Sclerosis
Interventions
Belumosudil (KD025), Placebo
Drug
Lead sponsor
Kadmon, a Sanofi Company
Industry
Eligibility
18 Years to 100 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
26
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Jun 10, 2026, 9:58 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

NCT07335562
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
BMS-986353, Fludarabine, Cyclophosphamide, Tocilizumab, Rituximab, Nintedanib
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
16 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
16
States / cities
Scottsdale, Arizona • Aurora, Colorado • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jun 10, 2026, 9:58 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis

NCT02465437
View directory record Official record
Conditions
Diffuse Cutaneous Systemic Sclerosis
Interventions
JBT-101, Placebo, Part B Open-Label Extension
Drug
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Jun 10, 2026, 9:58 AM EDT
Terminated Phase 1 Interventional

Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases

NCT00849745
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Systemic Sclerosis
Interventions
Nonmyeloablative allogeneic stem cell transplant
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years to 69 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Jun 10, 2026, 9:58 AM EDT
Not listed No phase listed Observational

Endothelial Biomarkers of Systemic Sclerosis-associated Pulmonary Hypertension

NCT03459716
View directory record Official record
Conditions
Scleroderma, Pulmonary Hypertension
Interventions
No intervention
Other
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
56 participants
Timeline
2018 – 2021
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Jun 10, 2026, 9:58 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Transcutaneous Electroacupuncture for Gastric Complications of Scleroderma

NCT03294616
View directory record Official record
Conditions
Scleroderma, Gastroparesis
Interventions
transcutaneous electroacupuncture
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Jun 10, 2026, 9:58 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rheumatology Patient Registry and Biorepository

NCT04402086
View directory record Official record
Conditions
Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jun 10, 2026, 9:58 AM EDT
Completed Phase 3 Interventional Results available

A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon

NCT00498615
View directory record Official record
Conditions
Raynaud, Scleroderma
Interventions
Fasudil
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2014 · Synced Jun 10, 2026, 9:58 AM EDT
Completed No phase listed Observational

MRI for Screening and Monitoring Scleroderma ILD

NCT05204355
View directory record Official record
Conditions
Scleroderma
Interventions
MRI, Hyperpolarized Xe129, HRCT
Diagnostic Test · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jun 10, 2026, 9:58 AM EDT
Terminated Not applicable Interventional

UVA1 Light for Scleroderma and Similar Conditions

NCT00476697
View directory record Official record
Conditions
Keloid, Scleroderma, Scars, Granuloma Annulare, Acne Keloidalis Nuchae
Interventions
German manufactured UVA1 emitting light system
Device
Lead sponsor
University of Michigan
Other
Eligibility
10 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 26, 2015 · Synced Jun 10, 2026, 9:58 AM EDT
Completed Not applicable Interventional Results available

Botulinum Toxin in the Treatment of Raynaud's

NCT01233999
View directory record Official record
Conditions
Raynaud's Syndrome
Interventions
botulinum toxin A
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jun 10, 2026, 9:58 AM EDT
Withdrawn Phase 2Phase 3 Interventional

CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH

NCT03726398
View directory record Official record
Conditions
Interstitial Lung Disease, Scleroderma, Pulmonary Hypertension
Interventions
Opsumit 10 Mg Tablet
Drug
Lead sponsor
Franz Rischard, DO
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Jun 10, 2026, 9:58 AM EDT
Withdrawn Not applicable Interventional

Functional Luminal Imaging Probe (FLIP) Topography Use in Patients With Scleroderma and Trouble Swallowing

NCT03270722
View directory record Official record
Conditions
Scleroderma, Dysphagia, GERD - Gastro-Esophageal Reflux Disease
Interventions
FLIP topography, Upper Endoscopy
Device · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Jun 10, 2026, 9:58 AM EDT
Terminated Phase 1 Interventional

Safety and Value of Self Bone Marrow Transplants Following Chemotherapy in Scleroderma Patients

NCT00040651
View directory record Official record
Conditions
Scleroderma, Systemic Sclerosis
Interventions
Fludarabine, Cyclophosphamide, Thymoglobulin, Leukapheresis, Self bone marrow transplant
Drug · Procedure
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Jun 10, 2026, 9:58 AM EDT
Recruiting Phase 1 Interventional

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

NCT07115745
View directory record Official record
Conditions
Refractory Autoimmune Diseases
Interventions
BMS-986515, Fludarabine, Cyclophosphamide, Tocilizumab
Genetic · Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 10, 2026, 9:58 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Genetic Study of the FBN1 Gene and Fibrillin-1 Abnormalities in Choctaw Native Americans and Other Patients With Systemic Sclerosis

NCT00006393
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1998
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 10, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis

NCT02370693
View directory record Official record
Conditions
Lung Diseases, Interstitial, Systemic Sclerosis, Scleroderma
Interventions
Bortezomib, Placebo, Mycophenolate mofetil
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Jun 10, 2026, 9:58 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea

NCT03351114
View directory record Official record
Conditions
Morphea
Interventions
Crisaborole
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 31, 2021 · Synced Jun 10, 2026, 9:58 AM EDT